A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Fiche publication
Date publication
septembre 2018
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAUCHESNE Patrick, Pr GHIRINGHELLI François
Tous les auteurs :
Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J
Lien Pubmed
Résumé
We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients with recurrent glioblastoma who had progressed after first-line treatment with radiotherapy, temozolomide, and BEV.
Mots clés
Clinical trial, Continuous bevacizumab, Overall survival, Recurrent glioblastoma
Référence
Oncologist. 2018 Sep 28;: